睿知中国疾病研究地图
候选清单0

即将招募鼻咽癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma

ClinicalTrials.gov 上登记的一项鼻咽癌开放试验,由广西医科大学第一附属医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方广西医科大学第一附属医院First Affiliated Hospital of Guangxi Medical University南宁医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06680115,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma;

    入选标准第 1 条

  3. Staging TanyN3M0 (AJCC/UICC 9th edition) ;

    入选标准第 3 条

  4. Received systemic sex hormone or other immunosuppressive therapy with equivalent dose > 10mg prednisone/day within 28 days before signing the informed consent. Participants with a systemic sex hormone dose ≤10mg prednisone/day or inhaled/topical corticosteroids were enrolled;

    排除标准第 5 条

  5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;

    入选标准第 4 条

  6. White blood cell≥3.5×10\^9/L,Neutrophils≥1.5×10\^9/L, hemoglobin≥ 90 g/L, platelet (PLT)≥ 100x10\^9/ L ;

    入选标准第 5 条

    Transaminases≤2.5 times the upper limit of normal, total bilirubin <1.5 times the upper limit of normal;

    入选标准第 6 条

    Creatinine clearance ≥60 ml/min;

    入选标准第 7 条

  7. HBsAg positive and HBV DNA >1×103 copy/ml;

    排除标准第 1 条

    Patients with positive HCV antibody test results;

    排除标准第 2 条

    Had other malignancies within 5 years, except carcinoma in situ, adequately treated non-melanoma skin cancer, and papillary thyroid cancer;

    排除标准第 8 条

    Human immunodeficiency virus (HIV) infection;

    排除标准第 10 条

  8. Pregnant or lactating women (pregnancy tests should be considered for sexually active, fertile women);

    排除标准第 7 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06680115,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma;
  2. Age≥18 years;
  3. Staging TanyN3M0 (AJCC/UICC 9th edition) ;
  4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
  5. White blood cell≥3.5×10\^9/L,Neutrophils≥1.5×10\^9/L, hemoglobin≥ 90 g/L, platelet (PLT)≥ 100x10\^9/ L ;
  6. Transaminases≤2.5 times the upper limit of normal, total bilirubin <1.5 times the upper limit of normal;
  7. Creatinine clearance ≥60 ml/min;
  8. Signed informed consent form.

排除标准:Exclusion Criteria:

  1. HBsAg positive and HBV DNA >1×103 copy/ml;
  2. Patients with positive HCV antibody test results;
  3. Active, known, or suspected autoimmune disease. Participants with type 1 diabetes, hypothyroidism requiring hormone replacement therapy, and skin conditions that do not require systemic treatment, such as vitiligo, psoriasis, or hair loss, may be enrolled;
  4. History of interstitial lung disease;
  5. Received systemic sex hormone or other immunosuppressive therapy with equivalent dose > 10mg prednisone/day within 28 days before signing the informed consent. Participants with a systemic sex hormone dose ≤10mg prednisone/day or inhaled/topical corticosteroids were enrolled;
  6. Have received or will receive live vaccine within 30 days before signing the informed consent;
  7. Pregnant or lactating women (pregnancy tests should be considered for sexually active, fertile women);
  8. Had other malignancies within 5 years, except carcinoma in situ, adequately treated non-melanoma skin cancer, and papillary thyroid cancer;
  9. The subject is known to have a prior allergy to macromolecular protein preparations, or any of the components of sindillizumab;
  10. Human immunodeficiency virus (HIV) infection;
  11. Other conditions, as determined by the investigator, that may affect subjects' safety or compliance with the study include symptomatic heart failure, unstable angina pectoris, myocardial infarction, active infection requiring systemic treatment, mental illness, or family and social factors.

引自 ClinicalTrials.gov, NCT06680115, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06680115,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06680115